Opus Genetics, INC Form 4 insider transactions

Opus Genetics' Head of Financial Quality Assurance, Amy Zaremba, reported a disposition of 3,390 common shares to cover tax obligations related to an RSU vesting.

Amy Zaremba Rabourn, Head of Financial Quality Assurance at Opus Genetics, reported the disposition of 3,950 common shares for tax withholding purposes.

Opus Genetics Director Cam Gallagher was granted 67,000 restricted stock units, vesting in December 2026.

Opus Genetics Director James S.J. Manuso was granted 31,188 shares of common stock in lieu of cash for 2026 board services.

Opus Genetics Director Adrienne L Graves was granted 23,643 shares of common stock in lieu of cash for 2026 board services, increasing her beneficial ownership to 103,147 shares.

Opus Genetics Director Jean Bennett was granted 21,127 shares of common stock as compensation for her 2026 board services.

Opus Genetics Director Sean Ainsworth was granted 42,507 shares of common stock in lieu of cash for 2026 board services.

Opus Genetics Director Cam Gallagher reported significant stock purchases and restricted stock unit grants, increasing his beneficial ownership.

Foundation Fighting Blindness Retinal Degeneration Fund reported the sale of 4 million shares of Opus Genetics, Inc. common stock at $2.15 per share.

Opus Genetics CEO George Magrath filed an amendment to clarify a stock transaction was for tax withholding, not an open market sale.

Opus Genetics CEO George Magrath disposed of 30,350 shares of common stock at $2.3 per share to cover tax withholding obligations.

Opus Genetics President Benjamin R Yerxa disposed of 23,795 shares of common stock at $1.95 per share to cover tax withholding obligations.

Opus Genetics' Chief Financial Officer, Robert E. Gagnon, received grants of 200,000 restricted stock units and 250,000 employee stock options.

Opus Genetics Director Cam Gallagher plans to acquire 869,565 shares of common stock at $1.15 per share on August 25, 2025, increasing direct beneficial ownership to 1,810,430 shares.

Opus Genetics Director Sean Ainsworth acquired 86,956 shares of common stock at $1.15 per share, increasing his direct beneficial ownership.

Foundation Fighting Blindness reports the conversion of Series A non-voting convertible preferred stock into common stock of Opus Genetics following stockholder approval.

Director Richard J. Rodgers acquired 79,504 shares of common stock and options to purchase 79,592 shares of common stock in Opus Genetics, Inc. on April 30, 2025.

Director James S. Manuso of Opus Genetics, Inc. was granted 79,504 shares of common stock and options to purchase 79,592 shares on April 30, 2025.

Director Adrienne L. Graves received a grant of restricted stock units and stock options from Opus Genetics, Inc. on April 30, 2025.

Director Cam Gallagher of Opus Genetics, Inc. reports acquisition of common stock and stock options.

Director Susan Benton acquired 79,504 shares of common stock and options to purchase 79,592 shares of common stock from Opus Genetics on April 30, 2025.

Director Jean Bennett acquired shares and options in Opus Genetics, Inc. on April 30, 2025, through a grant of restricted stock units and stock options.

Director Sean Ainsworth of Opus Genetics, Inc. reports acquisition of restricted stock units and stock options.

CEO George Magrath acquired shares and warrants of Opus Genetics in a transaction exempt from Section 16(b) of the Securities Exchange Act of 1934.

Director Cam Gallagher acquired shares and warrants of Opus Genetics, Inc. in a transaction exempt from Section 16(b) of the Securities Exchange Act of 1934.

Chief Operating Officer of Opus Genetics, Joseph Schachle, reports the acquisition of restricted stock units and stock options.

Amy Zaremba Rabourn, SVP of Finance at Opus Genetics, reports the acquisition of stock options and restricted stock units in the company.

CEO of Opus Genetics, George Magrath, receives a grant of restricted stock units and an employee stock option.

Nirav S. Jhaveri, CFO of Opus Genetics, received grants of restricted stock units and employee stock options on March 13, 2025.

Ashwath Jayagopal, Chief Scientific & Development Officer of Opus Genetics, reports the acquisition of restricted stock units and stock options.